IPO Roundup: AMTD International, InMode LTD each find their footing after going public
The two international companies are both up since they started trading in New York this week
Sector
Health
1090 stories · page 53 of 55
Acasti Pharma reiterated as Speculative Buy by Mackie after FDA setback news for competitor Amarin
Amarin had recently indicated that they did not think they would need an FDA adcom meeting for their sNDA (supplemental new drug application) for Vascepa
IXICO says it is on track to meet market expectations as it gives an upbeat assessment of prospects
The company’s technology is used to interpret brain scans and is deployed by drug developers to aid with clinical trial
Next Green Wave says CEO and executive chairman Leigh Hughes resigns due to health, personal priorities, continues as advisor
Hughes commented: "I took over as CEO in January 2019 to lead NGW through a difficult formative period. NGW is now in a strong position to continue its growth cycle"
VolitionRx forms new Texas veterinary subsidiary, taps animal health expert Nathan Dewsbury to head it
Volition's NuQ diagnostic blood tests pinpoints irregular levels of nucleosomes in the blood, which indicate cancer
Propanc Biopharma moves closer to first-in-human study by quantifying ingredients for its metastatic cancer drug
This step allows Propanc to move forward in discussions with potential sites for its clinical trial, which the company expects to launch in early 2020
LexaGene to beta test its rapid pathogen detector at Assurance Scientific Laboratories
The company's LX Analyzer will test urine samples for pathogens and screen for antimicrobial resistance markers
CytoDyn files Phase 2 protocol with FDA for use of leronlimab and regorafenib as combo therapy for metastatic colorectal cancer
The 30-patient study is designed to test the hypothesis that a combination of injected leronlimab and regorafenib taken orally will increase progression-free survival in patients with CCR5-positive metastatic colorectal cancer
Hemispherx reports positive survival data linked to stage 4 ovarian cancer using Ampligen as a combination therapy
Based on the Phase 1 study results, the company said that a new Phase 2 recurrent ovarian cancer clinical study has already begun at the University of Pittsburgh Medical Center
ROBO Global ranks Qiagen NV as the No 1 company in molecular diagnostics
Senior research analyst Nina Deka says the Netherlands-based company has four new platforms to go after a $4 billion market opportunity
Nemaura launches shipments of its SugarBEAT glucose monitor to the UK
The SugarBEAT works for patients with diabetes or prediabetes by testing their blood glucose levels using a sensor on the skin, rather than using a needle
Shield Therapeutics hopes to have US commercial partner by the year-end; gaining traction for key product in Europe
The updates were provided alongside the company's interim results
Paradigm Biopharmaceuticals files Investigational New Drug submission for ZilosulÒ with FDA
ZilosulÒ (iPPS) is a potential first-line therapeutic treatment for osteoarthritis and other diseases affecting the musculoskeletal system.
PreveCeutical grants Asterion Cannabis option to purchase 51% interest in Sol-Gel intellectual property
The firm's sustained-release Sol-Gel (soluble gel) program allows for the nasal delivery of medical compounds, including cannabinoids like CBD
Verona Pharma PLC excited about the progress of ensifentrine through clinical trials
Recent trial results support the view that the drug could be an effective bronchodilator in COPD patients via various delivery methods
Zynerba boosts cash position in 2Q, gears up for top-line data from key trials with Zygel CBD gel
The company has a cash pile of $88.7 million to fund operations and reach clinical milestones in the first half of 2020
Faron Pharmaceuticals bags first part of £2.8mln fundraising
The cash will allow the company to continue clinical development of its lead cancer drug and provide working capital while a partner is sought
XPhyto Therapeutics is taking a scientific approach to medical cannabis with a unique business model
XPhyto’s CEO Hugh Rogers shares his unique insights on taking a scientific approach to cannabis, bridging the gap between medical marijuana and clinical validation and why the company - which has floated on the CSE today - focused on German
CytoDyn marks major milestone for its leronlimab drug with first step into field of cancer
A first patient is being treated under emergency investigational new drug regulations of the US Food and Drug Administration
ValiRx updates on JV discussions and switches NOMAD
The company said it also expects to receive a tax credit shortly